Related Experiment Video
Updated: May 22, 2026
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
Triptolide inhibits proliferation and invasion of malignant glioma cells
Haipeng Zhang1, Wenbo Zhu, Xingwen Su
1Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-Sen University, 74 Zhongshan Road II, Guangzhou, 510080, People's Republic of China.
Abstract:
Malignant glioma is the most devastating and aggressive tumor in brain, characterized by rapid proliferation and diffuse invasion. Chemotherapy and radiotherapy are the pivotal strategies after surgery; however, high drug resistance of malignant glioma and the blood-brain barrier usually render chemotherapy drugs ineffective. Here, we find that triptolide, a small molecule with high lipid solubility, is capable of inhibiting proliferation and invasion of malignant glioma cells effectively. In both investigated malignant glioma cell lines, triptolide repressed cell proliferation via inducing cell cycle arrest in G0/G1 phase, associated with downregulation of G0/G1 cell cycle regulators cyclin D1, CDK4, and CDK6 followed by reduced phosphorylation of retinoblastoma protein (Rb). In addition, triptolide induced morphological change of C6 cells through downregulation of protein expression of MAP-2 and inhibition of activities of GTPases Cdc42 and Rac1/2/3, thus significantly suppressing migratory and invasive capacity. Moreover, in an in vivo tumor model, triptolide delayed growth of malignant glioma xenografts. These findings suggest an important inhibitory action of triptolide on proliferation and invasion of malignant glioma, and encourage triptolide as a candidate for glioma therapy.
Insights
Triptolide effectively inhibits malignant glioma cell proliferation and invasion by inducing cell cycle arrest and suppressing cell migration. This natural compound shows promise as a potential therapy for brain tumors, including gliomas.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Pharmacology
Background:
- Malignant glioma is an aggressive brain tumor with poor prognosis.
- Current treatments like chemotherapy and radiotherapy are limited by drug resistance and the blood-brain barrier.
Purpose of the Study:
- To investigate the efficacy of triptolide, a lipid-soluble small molecule, in inhibiting malignant glioma proliferation and invasion.
- To elucidate the molecular mechanisms underlying triptolide's anti-glioma effects.
Main Methods:
- In vitro studies using malignant glioma cell lines to assess proliferation, cell cycle, and migration.
- In vivo studies using a xenograft tumor model to evaluate triptolide's effect on tumor growth.
- Analysis of cell cycle regulators (cyclin D1, CDK4, CDK6, Rb) and proteins involved in cell morphology and migration (MAP-2, Cdc42, Rac1/2/3).
Main Results:
- Triptolide significantly inhibited malignant glioma cell proliferation by inducing G0/G1 cell cycle arrest.
- Triptolide reduced cell migration and invasion by altering cell morphology and inhibiting GTPase activities.
- Triptolide treatment delayed tumor growth in an in vivo glioma xenograft model.
Conclusions:
- Triptolide demonstrates potent anti-proliferative and anti-invasive activity against malignant glioma.
- Triptolide's mechanisms involve cell cycle regulation and modulation of cellular migration pathways.
- Triptolide represents a promising therapeutic candidate for glioma treatment.
